• Life Science Venture Capital Investment News Round Up – 2 April 2012

    by  • April 2, 2012 • Uncategorized

    Highlights from recent Life Science venture capital news.

     

    28.03.2012 – Santa Barbara, CA

    Sientra Raises $65 Million in a Series C Financing

    Sientra, a privately-held medical device company focused on the aesthetic and plastic surgery markets, announced today that it closed on its $65 million Series C financing led by Abingworth and with participation by Clarus Ventures, OrbiMed Advisors and all other insiders. The new funds bolster Sientra’s treasury and will support full commercialization of its recently FDA-approved portfolio of Silicone Breast Implants, as well as fund general operations and provide working capital.http://finance.yahoo.com/news/sientra-raises-65-million-series-185400463.html

     

    28.03.2012 – Redwood City, CA

    Relievant Medsystems Raises $30M in Series D Financing

    Relievant Medsystems Inc., a Redwood City, Calif.-based medical device company focused on basivertebral nerve ablation for the treatment of chronic axial low back pain, has raised $30m in Series D financing. The round was led by New Enterprise Associates, with participation from existing investors Canaan Partners, Emergent Medical Partners, Morgenthaler Ventures and ONSET Ventures. http://www.finsmes.com/2012/03/relievant-medsystems-raises-30m-series-financing.html


    23.03.2012 – San Antonio, TX

    BiO2 Medical Secures Series B Round Funding

    BiO2 Medical, Inc., a Texas based medical device manufacturer with corporate offices in San Antonio, Texas, and R&D and manufacturing operations in Golden, Colorado, has recently completed its $13.7M Series B round of funding, which included the conversion of a $1M State of Texas Emerging Technology Fund (ETF) award. The round was led by San Antonio’s Targeted Technology Fund and BiO2 Medical’s investment bankers, Pasadera Capital. http://www.prnewswire.com/news-releases/bio2-medical-secures-series-b-round-funding-143997616.html


    30.03.2012 – New York, NY

    Genalyte Raises $11.8M in Series B Round

    Genalyte today announced the completion of a Series B financing that raised $11.8 million. The funds will primarily go toward commercializing its Maverick platform and highly multiplexed panels for autoimmune and immunoassay applications, the company said. New investors Redmile Group and Claremont Creek Ventures participated in the round along with private investors from Genalyte’s Series A financing round. http://www.genomeweb.com/mdx/multiplexing-technology-firm-genalyte-raises-118m-series-b-round

     

    Europe

    Secondary Venture Round

    28.03.2012 – Mont-Saint-Guibert, Belgium

    Promethera closes series B

    Liver disease company Promethera Biosciences S.A. (Mont-Saint-Guibert, Belgium) raised EUR 17 million ($22.5 million) in a series B round and secured a EUR 6.6 million ($8.7 million) government loan from the Walloon region of Belgium. New investors Boehringer Ingelheim Venture Fund; the venture arm of Shire plc (LSE:SHP; NASDAQ:SHPGY); Mitsui Global Investment; ATMI (NASDAQ:ATMI); and Sambrinvest participated in the round. Promethera’s existing investors are Vesalius Biocapital Partners; Société Régionale d’Investissement de Wallonie; Vives-Louvain Technology Fund; Life Science Research Partners; NivelInvest; Fianciere Spin-Off Luxembourgeoise; Sopartec; and angel investors. http://www.biocentury.com/dailynews/financial/2012-03-28/promethera-closes-series-b


    This Week In Venture Capital is brought to you by VM Index from Venture Market Intelligence – Venture Capital made easier

    VM Index is an online Life Science, Med Tech & Biotech venture capital funding tool with expert data that enables companies to raise more money, faster and at a better valuation than they could otherwise.

    About